Point-of-care ultrasound innovator Exo has acquired Medo AI of Edmonton, Alberta, with plans to soon make ultrasound imaging “as easy as snapping a photo on a smartphone.”
Exo, based in Redwood City, Calif., says it hopes Medo’s two FDA-cleared, ultrasound-specific algorithms will help open POCUS to clinical departments across health systems and around the world.
Exo further bases its confidence in Medo’s stable relationships with provider organizations in Asia as well as Canada, according to a July 26 news release.
The company adds that the two companies’ combined technical capacity will allow clinicians short on ultrasound know-how to leverage automated image-interpretation as well as image-acquisition capabilities.
The purchase “is about bringing unprecedented ease of use to ultrasound imaging — allowing caregivers to easily obtain and interpret ultrasound images,” says Exo founder and CEO Sandeep Akkaraju. “Medo has built a robust AI pipeline to go from acquiring medical images to FDA-cleared software.”
Medo CEO Dornoosh Zonoobi adds that the companies share a vision in which ease of imaging and immediacy of diagnostic information “will radically transform medical care, creating a world where caregivers can image the body as easily as snapping a photo on a smartphone.”
Last year Exo launched an ultrasound workflow solution called Exo Works after raising investments of $220 million.
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.